Axsome Therapeutics (AXSM) EBT Margin (2022 - 2026)
Axsome Therapeutics (AXSM) posted EBT Margin of 33.76% for Q1 2026, down 135.21% sequentially from 14.35% in Q4 2025, and up 1516.0% YoY from 2.09% in Q1 2025.
Powered by 
Analysis
Axsome Therapeutics (AXSM) EBT Margin (2022 - 2026) Analysis & Trends
Axsome Therapeutics has reported EBT Margin for 5 years, with the latest figure at 33.76% in Q1 2026.
- Quarterly EBT Margin rose 1516.0% year-over-year to 33.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26.66% (up 6196.0% YoY) and the FY2025 annual result came in at 28.77%, up 4567.0% from the prior year.
- EBT Margin eased to 33.76% in Q1 2026 per AXSM's latest filing, from 14.35% in the prior quarter.
- Over five years, EBT Margin peaked at 9.13% in Q1 2023 and troughed at 14965.4% in Q4 2024.
- A 5-year average of 1047.2% and a median of 91.09% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin sank 1482703 bps in 2024, then jumped 1495105 bps in 2025.
- Over 5 years, EBT Margin stood at 251.29% in 2022, then surged by 45 bps to 138.37% in 2023, then tumbled by 10716 bps to 14965.4% in 2024, then jumped by 100 bps to 14.35% in 2025, then slumped by 135 bps to 33.76% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 33.76%, 14.35%, and 27.62% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn | -23.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.44% |
| Mar 31, 2026 | -33.76% |
| Dec 31, 2025 | -14.35% |
| Sep 30, 2025 | -27.62% |
| Jun 30, 2025 | -32.61% |
| Mar 31, 2025 | -48.91% |
| Dec 31, 2024 | -14,965.40% |
| Sep 30, 2024 | -61.67% |
| Jun 30, 2024 | -91.03% |
| Mar 31, 2024 | -91.14% |
| Dec 31, 2023 | -138.37% |
| Sep 30, 2023 | -108.80% |
| Jun 30, 2023 | -145.15% |
| Mar 31, 2023 | -9.13% |
| Dec 31, 2022 | -251.29% |
| Sep 30, 2022 | -266.08% |
| Jun 30, 2022 | -469.82% |